Arbutus Biopharma reports $93.7 million in cash and marketable securities in Q3 2025

Reuters11-13

<a href="https://laohu8.com/S/ABUS">Arbutus Biopharma</a> reports $93.7 million in cash and marketable securities in Q3 2025

Arbutus Biopharma Corp. reported cash, cash equivalents, and marketable securities of $93.7 million as of September 30, 2025, down from $122.6 million at the end of 2024. Total revenue for the third quarter was $0.5 million, compared to $1.3 million in the same period last year, reflecting a decrease in license royalty revenues. Research and development expenses declined to $5.8 million from $14.3 million, while general and administrative expenses decreased to $3.0 million from $4.5 million, attributed to organizational streamlining and cost-cutting measures. The net loss for the quarter was $7.7 million, or $0.04 per share, compared to a net loss of $19.7 million, or $0.10 per share, in the third quarter of 2024. Business developments included a focus on advancing clinical programs for imdusiran and AB-101, organizational restructuring, and ongoing litigation with Moderna and Pfizer-BioNTech.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574829-en) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583567605?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583567605","market":"fut","top_or_hot":-1,"title":"Arbutus Biopharma reports $93.7 million in cash and marketable securities in Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABUS\">Arbutus Biopharma</a> reports $93.7 million in cash and marketable securities in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arbutus Biopharma Corp. reported cash, cash equivalents, and marketable securities of $93.7 million as of September 30, 2025, down from $122.6 million at the end of 2024. Total revenue for the third quarter was $0.5 million, compared to $1.3 million in the same period last year, reflecting a decrease in license royalty revenues. Research and development expenses declined to $5.8 million from $14.3 million, while general and administrative expenses decreased to $3.0 million from $4.5 million, attributed to organizational streamlining and cost-cutting measures. The net loss for the quarter was $7.7 million, or $0.04 per share, compared to a net loss of $19.7 million, or $0.10 per share, in the third quarter of 2024. Business developments included a focus on advancing clinical programs for imdusiran and AB-101, organizational restructuring, and ongoing litigation with <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> and Pfizer-BioNTech.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574829-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arbutus Biopharma reports $93.7 million in cash and marketable securities in Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArbutus Biopharma reports $93.7 million in cash and marketable securities in Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABUS\">Arbutus Biopharma</a> reports $93.7 million in cash and marketable securities in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arbutus Biopharma Corp. reported cash, cash equivalents, and marketable securities of $93.7 million as of September 30, 2025, down from $122.6 million at the end of 2024. Total revenue for the third quarter was $0.5 million, compared to $1.3 million in the same period last year, reflecting a decrease in license royalty revenues. Research and development expenses declined to $5.8 million from $14.3 million, while general and administrative expenses decreased to $3.0 million from $4.5 million, attributed to organizational streamlining and cost-cutting measures. The net loss for the quarter was $7.7 million, or $0.04 per share, compared to a net loss of $19.7 million, or $0.10 per share, in the third quarter of 2024. Business developments included a focus on advancing clinical programs for imdusiran and AB-101, organizational restructuring, and ongoing litigation with <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> and Pfizer-BioNTech.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574829-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLm8cNf:1","article_id":"2583567605","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583567605","pubTimestamp":1763037048,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arbutus Biopharma Corp. reported cash, cash equivalents, and marketable securities of $93.7 million as of September 30, 2025, down from $122.6 million at the end of 2024. Total revenue for the third quarter was $0.5 million, compared to $1.3 million in the same period last year, reflecting a decrease in license royalty revenues. Research and development expenses declined to $5.8 million from $14.3 million, while general and administrative expenses decreased to $3.0 million from $4.5 million, attributed to organizational streamlining and cost-cutting measures. The net loss for the quarter was $7.7 million, or $0.04 per share, compared to a net loss of $19.7 million, or $0.10 per share, in the third quarter of 2024. Business developments included a focus on advancing clinical programs for imdusiran and AB-101, organizational restructuring, and ongoing litigation with Moderna and Pfizer-BioNTech.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BNTX":"BioNTech SE","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4535":"淡马锡持仓","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4588":"碎股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4112":"金融交易所和数据","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4548":"巴美列捷福持仓","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999002232.USD":"Allianz Global High Payout USD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4581":"高盛持仓","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4599":"减肥药","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4501":"段永平概念","ABUS":"Arbutus Biopharma Corporation","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"translate_title":"Arbutus Biopharma报告2025年第三季度现金和有价证券为9370万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"BNTX":0.9,"ABUS":0.9,"NDAQ":0.9},"content_text":"Arbutus Biopharma reports $93.7 million in cash and marketable securities in Q3 2025\n    \n\n        Arbutus Biopharma Corp. reported cash, cash equivalents, and marketable securities of $93.7 million as of September 30, 2025, down from $122.6 million at the end of 2024. Total revenue for the third quarter was $0.5 million, compared to $1.3 million in the same period last year, reflecting a decrease in license royalty revenues. Research and development expenses declined to $5.8 million from $14.3 million, while general and administrative expenses decreased to $3.0 million from $4.5 million, attributed to organizational streamlining and cost-cutting measures. The net loss for the quarter was $7.7 million, or $0.04 per share, compared to a net loss of $19.7 million, or $0.10 per share, in the third quarter of 2024. Business developments included a focus on advancing clinical programs for imdusiran and AB-101, organizational restructuring, and ongoing litigation with Moderna and Pfizer-BioNTech.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574829-en) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583567605","isCrawlerRequest":true}